One of the most notable portfolio realignments in medtech this year comes from Johnson & Johnson MedTech, as the company prepares to separate its legacy orthopedics unit into a standalone business. The move caps nearly two years of internal restructuring and aligns with a wider industry pattern: leading strategics such as Stryker and Medtronic have been rebalancing their portfolios, spinning off slower-growth or non-core segments to focus resources on high-growth therapeutic markets.